Live
10x Genomics Blog10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com10x Genomics Blog10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda - Stock TitanFierceBiotechCity aims to lay foundation for RNAi renaissance with nearly $100M series BEndpoints News#ADA26: AstraZeneca GLP-1 pill cuts weight 10.5% after six monthsRoche MediaRoche and Nurix Therapeutics Announce Global Collaboration | PharmExec - Pharmaceutical ExecutiveBioPharma DiveCity banks nearly $100M for next-gen RNAi drugsEndpoints NewsIncyte CEO sees $2B Vega deal aiding a post-Jakafi futureClinical OMICsCortical On/Off Switch Provides Sleep Benefits to Awake MiceClinical OMICsGLP-1 Drugs Linked to Lower Rates of Substance Use DisordersEndpoints NewsCity Therapeutics gets $99M to gather data on three RNAi medicinesClinical OMICsProPure™ Endotoxin-Free Proteins for Reliable Cancer ResearchClinical OMICsTARGA Imager Enables High-Resolution Imaging of Neurodevelopmental Models
Endpoints News 11. Dez. 2025

Rhythm reports Imcivree’s key weight loss data from Phase 2 Prader-Willi trial

Rhythm reports Imcivree’s key weight loss data from Phase 2 Prader-Willi trial

Original
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.